Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical metformin as an adjunct to daylight photodynamic therapy for actinic keratosis
2025-520798-38-00Phase 2Authorised
- Sponsor
- IIS Aragón
- Start
- Jan 2025
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of metformin and methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by IIS Aragón. Primary endpoint: Clinical efficacy and adverse effects over treatment and follow-up. Planned start Jan 2025; status: authorised.
02
Drugs
metforminmethyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2025-520798-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520798-38-00.